Akeso, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AKESF | GMAB | 9966.HK | 2616.HK | 4583.T | RCUS | |
|---|---|---|---|---|---|---|
| Market cap | 9.66B | 32.43B | 6.43B | 8.98B | 6.73B | 2.22B |
| P/E (TTM) | — | 41.5 | — | — | — | — |
| Forward P/E | — | 33.4 | -21.0 | 137.0 | -2.8 | -5.7 |
| Price/book | 7.6 | 5.3 | 3.3 | 5.9 | 4.2 | 3.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −23.60% | +91.12% | −39.84% | −7.84% | −35.11% | −1.28% |
| Today | +4.90% | −4.32% | +1.68% | +4.16% | −2.35% | −8.39% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All AKESF news ›Ivonescimab Plus Chemotherapy Improves OS and PFS in Advanced Biliary Tract Cancer – Akeso Biopharma
Akeso Biopharma shared on LinkedIn: “We are proud to share the positive Phase III HARMONiGI1 results for ivonescimab plus chemotherapy in first-line advanced biliarytractcancer (BTC), presented today at the ESMO2026 Presidential Symposium.…
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 /…
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with ... HONG KONG, Dec. 15, 2023…
Akeso, Inc.: Relative Strength Chart - Stock Hong Kong S.E.
Compare Akeso, Inc. with the company of your choice via a Relative Strength chart. Real-time 9926 price, Hong Kong S.E. stock exchange Relative Strength Chart Akeso, Inc. Biotechnology & Medical Research All financial news and data…
Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026
Summit Therapeutics Inc. noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific... noted that data from the Phase III…
Akeso, Inc. Doses First Patient in Phase III Perioperative Study of Cadonilimab in Colon Cancer
Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the... announced that the first patient has been dosed…
Ivonescimab Beat Imfinzi Regimen on Survival in China Bile Duct Cancer Trial, Akeso Says, as Details Await ESMO
An experimental antibody called ivonescimab, combined with chemotherapy, helped patients with advanced biliary tract cancer live longer than the standard pairing of Imfinzi and chemotherapy, its developer Akeso reports. The 682-patient…
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Oct 21, 2026, 08:42 ET Building on its strong clinical profile in the IO2.0 landscape, Akeso is advancing a comprehensive global development program for ivonescimab across multiple tumor types and treatment settings. As a cornerstone of…
Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer
BioPharma APAC - Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer 23 October 2026 | Friday | News Akeso, Inc. announced that Summ
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC. US clinical trial site activations are expected to begin in the fourth quarter of 2026.1 EA2251…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com1
- prnewswire.com1
- theglobeandmail.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.